For regular insulin in biphasic insulin
formulation, 1 ml of sample was added to 4 [micro]l of 5M HCl, mixed well, allowed to stand for 1 h.
Premixed insulin preparations consist of fixed proportions of basal and bolus components (premixed NPH/regular human insulin 70/30, biphasic insulin
lispro 75/25, and biphasic insulin
achieved the primary endpoint of non-inferiority to biphasic insulin
aspart 30 for mean change in HbA[sub.
Attainment of glycaemic goals in type 2 diabetes with once-, twice- or thrice-daily dosing with biphasic insulin
aspart 70/30 (The 1-2-3 study).
Patients with Type II Diabetes who used the biphasic insulin
saw their blood glucose levels drop by up to 31 per cent and episodes of major hypoglycaemia, where the glucose levels become very low, fell by an average of 94 per cent" explained Professor Paul Valensi, head of the Department of Endocrinology-Diabetology-Nutrition at the Jean Verdier Hospital in France, who led the research.
The multinational BOOST(TM) INTENSIFY PREMIXI trial was a 26-week, randomised, controlled open-label, treat-to-target trial comparing the efficacy and safety of Ryzodeg and biphasic insulin
aspart 30, both administered twice-daily with or without oral antidiabetic drugs in adult patients with type 2 diabetes previously treated with premixed or self-mixed insulin either once- or twice-daily.
of dose titration, is a potential alternative to biphasic insulin
4) In a recently published trial, Raskin and colleagues (5) demonstrated that these HbA1c targets could be met with twice-daily biphasic insulin
aspart 30 and that more patients met target than when they received once-daily glargine (Fig.
In a retrospective examination of studies (see below) evaluating the use of GlycoMark to monitor exenatide, pramlintide, sitagliptin, and biphasic insulin
therapies, GlycoMark reflected changes in after-meal glucose levels more dynamically than A1C in moderately controlled patients - underscoring the ability of GlycoMark to detect underlying treatment effects on after-meal glucose not revealed by A1C.
A comparison of twice-daily exenatide and biphasic insulin
aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A noninferiority study.
A second study presented at the meeting showed that exenatide's effect on glycemic control is similar to that of conventional twice-daily biphasic insulin
, but without the inconvenience of ongoing titration, and that the drug--an injectable incretin mimetic--produces weight loss instead of weight gain.
in studies with other drug agents such as sitagliptin (Januvia), biphasic insulin
aspart 70/30 (Novolog Mix 70/30) in the INITIATE Trial, and lispro insulin mixture (Humalog Mix) in the DURABLE trial.